Telbivudine Prevents Vertical Transmission of Hepatitis B Virus From Women With High Viral Loads: A Prospective Long-Term Study

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1170-1176

  Wu, Quanxin ^a,b   Huang, Hongfei ^a,b   Sun, Xiaowen ^a,b   Pan, Meimin ^c   He, Yun ^d   Tan, Shun ^a,b   Zeng, Yi ^e   Li, Li ^a   Deng, Guohong ^a,b   Yan, Zehui ^a,b   He, Dengming ^a,f   Li, Junnan ^a   Wang, Yuming ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing   (China)

^c The Third Hospital of Changsha   (China)

^d 309TH HOSPITAL OF PLA   (China)

^e The First People's Hospital of Zigong City   (China)

^f 88th Hospital of Chinese People's Liberation Army   (China)

Author keywords

Antiviral Drug; Neonate; Nucleoside Analogue; Perinatal

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; THYMIDINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATION PERIOD; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; OPEN STUDY; PREGNANT WOMAN; PROSPECTIVE STUDY; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; BLOOD; CHINA; CLINICAL TRIAL; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; THYMIDINE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84930378505     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.043     Document Type: Article

References (31)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. JViral Hepat 2004, 11:97-107.
2. Deng M., Zhou X., Gao S., et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012, 9:185.
3. Jonas M.M. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009, 29:133-139.
4. del Canho R., Grosheide P.M., Mazel J.A., et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997, 15:1624-1630.
5. Wen W.H., Chen H.L., Ni Y.H., et al. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Hepatology 2011, 53:429-436.
6. Yin J., Zhang H., He Y., et al. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010, 19:777-786.
7. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49:S185-S195.
8. Han L., Zhang H.W., Xie J.X., et al. Ameta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011, 17:4321-4333.
9. Standring D.N., Bridges E.G., Placidi L., et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001, 12(Suppl 1):119-129.
10. Bridges E. 388 telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. JHepatol 2006, 44:S147.
11. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. NEngl J Med 2007, 357:2576-2588.
12. Bacq Y. Hepatitis B and pregnancy. Gastroenterol Clin Biol 2008, 32:S12-S19.
13. Pande C., Sarin S.K., Patra S., et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. JViral Hepat 2013, 20:801-810.
14. Zou H., Chen Y., Duan Z., et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. JViral Hepat 2012, 19:e18-e25.
15. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185. European Association for the Study of the Liver.
16. Han G.R., Cao M.K., Zhao W., et al. Aprospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. JHepatol 2011, 55:1215-1221.
17. Pan C.Q., Mi L.J., Bunchorntavakul C., et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012, 57:2423-2429.
18. Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. JViral Hepat 2009, 16:94-103.
19. Li X.M., Yang Y.B., Hou H.Y., et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003, 9:1501-1503.
20. van Zonneveld M., van Nunen A.B., Niesters H.G., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. JViral Hepat 2003, 10:294-297.
21. Bridges E.G., Selden J.R., Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 2008, 52:2521-2528.
22. Yaqoob M., Mahmood F., Hanif G., et al. Etiology and genetic factors in clefts of lip and/or palate reported at children's hospital, Lahore, Pakistan. Indian J Hum Genet 2013, 19:136-143.
23. ter Borg M.J., Leemans W.F., de Man R.A., et al. Exacerbation of chronic hepatitis B infection after delivery. JViral Hepat 2008, 15:37-41.
24. Lin H.H., Wu W.Y., Kao J.H., et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. JGastroenterol Hepatol 2006, 21:605-609.
25. Pan C.Q., Han G.R., Jiang H.X., et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012, 10:520-526.
26. Buchanan C., Tran T.T. Management of chronic hepatitis B in pregnancy. Clin Liver Dis 2010, 14:495-504.
27. Wang J., Zhu Q., Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J (Engl) 2002, 115:1510-1512.
28. Yang J., Zeng X.M., Men Y.L., et al. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus-a systematic review. Virol J 2008, 5:100.
29. Pan C.Q., Zou H.B., Chen Y., et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013, 11:1349-1355.
30. Jiang S.Z., Gao Z.Y., Li T., et al. T3098C and T53C mutations of HBV genotype C is associated with HBV infection progress. Biomed Environ Sci 2009, 22:511-517.
31. Palumbo E. Hepatitis B genotypes and response to antiviral therapy: a review. Am J Ther 2007, 14:306-309.